Vir Biotechnology Projects Cash Runway into Second Half of 2028 Amid Key Clinical Milestones
Vir Biotechnology (VIR) has provided updated guidance regarding its financial stability and clinical pipeline progress. The company expects to maintain a sufficient cash runway extending into the second half of 2028, providing a significant buffer for ongoing research and development efforts. A major catalyst for the company is the anticipated top-line data from its ECLIPSE-1 study, which is expected in the third quarter of 2026. CEO Marianne De Backer noted that the company is entering a transformative period focused on advancing hepatitis delta treatments and establishing a differentiated oncology franchise.
Tickers: $VIR
Topics: earnings call hepatitis delta leadership changes oncology
Read the full article at Seeking Alpha
Part of the story Arvinas Projects Cash Runway Through Mid-2028 Amid Upcoming Clinical Readouts (2 articles)